• agbiopro

After Kymera's raise, Nurix nabs $120M as it too hones in on clinical work

Sanofi- and Gilead Sciences-backed Nurix Therapeutics is following suit with rival biotech Kymera in raising a major cash haul for its protein modulation R&D work.

3 views0 comments
Send Us a Message

Alonei Abba

  • White LinkedIn Icon
  • White Facebook Icon
  • White Twitter Icon
  • White Google+ Icon